Evidence map›Paper›PMID 42651695›Full record

ArticleBiology2026

Combinatorial Therapy with Long-Acting Tenofovir and Tizoxanide Controls Viral Replication and Liver Inflammation in a Murine AAV-HBV Model of Chronic Hepatitis B.

Mojisola O Ogunnaike, Ashrafi Sultana, Samiksha Raut, Weimin Wang, Grace Bybee, Howard E Gendelman, Benson J Edagwa, Natalia A Osna, Larisa Y Poluektova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mojisola O OgunnaikeDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-9686-5054
Ashrafi SultanaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Samiksha RautDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Weimin WangDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Grace BybeeDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-7831-0370
Benson J EdagwaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0003-1484-9331
Natalia A OsnaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-7498-0556
Larisa Y PoluektovaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-7339-8732

Funding

The Role of TP-R on Alcohol-Induced Multi-Organ Damage: Liver and HeartP50AA030407 · NIAAA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Carol A. Casey · 2023 to 2026
$7.9M
Prodrug Formulations Create Sustained-Release AntiretroviralsR01AI145542 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Benson Edagwa, Howard E Gendelman · 2019 to 2026
$5.3M
LASER ART for PrePR01AI158160 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI EDAGWA, BENSON, GENDELMAN, HOWARD E · 2021 to 2025
$3.5M
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis BR01AI163042 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Benson Edagwa, NATALIA ALEKSANDR OSNA · 2022 to 2026
$3.1M
Thymic selection of Foxp3+ regulatory T cellsR56AI088553 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LAFAILLE, JUAN · 2010 to 2010
$423k
NIAAA NIH HHS P50 AA030407NIAID NIH HHS R01 AI145542NIAID NIH HHS R01AI145542,NIAID NIH HHS R01 AI158160NIAID NIH HHS R01 AI163042NIAID NIH HHS R56 AI088553NIH HHS 1P50AA030407-23A1NIH HHS 1R01AI158160-21A1NIH HHS 1R01AI163042-22A1NIH HHS 1R61AI188553-25A1
6 · The paper itself

Abstract

Chronic hepatitis B (CHB) infection is a major risk factor for progressive cirrhosis and hepatocellular carcinoma. Persistent virus-induced inflammation alters liver function, leading to accelerated disease and increased mortality. Although lifelong treatment with nucleos(t)ide analogs (NAs) is highly effective at suppressing viral replication, covalently closed circular DNA (cccDNA) persists in hepatocytes to sustain chronic infection, underscoring the need for better interventions and combination therapies. The durable suppression of viral replication and restoration of immune responses through long-acting (LA) therapies offer a promising strategy for sustained HBV control. We transformed tizoxanide (TIZ), a broad-spectrum anti-infective and immunomodulatory agent, into a LA lipophilic prodrug formulation (NM2TIZ) for intramuscular or subcutaneous administration. NM2TIZ exhibited long-term stability during storage and was evaluated in AAV-HBV mice using monotherapy and combination therapy approaches with an LA tenofovir prodrug formulation (NM5TFV). NM5TFV reduced the HBV DNA levels by >2 log

Indexed as

anti-inflammatorycombination therapyHBVnucleoside analogstenofovirtizoxanide

Identifiers

PMID42651695
PMCPMC13510084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.